Key figures
2023 Highlights
2023 Revenue
| 2,389.8 Million euros | +3.0% organic growth in 2023 |
Revenue by Region in 2023
| 17% Asia-Pacific | 40% Americas | 43% EMEA |
| In millions of euros | 2023 | Contribution | Organic growth Q4 | Organic growth 2023 |
|---|---|---|---|---|
| Europe, Middle East and Africa | 1,026.6 | 43% | 11.2% | 4.1% |
| Americas | 956.4 | 40% | 7.7% | 1.7% |
| Asia-Pacific | 406.8 | 17% | 5.5% | 3.5% |
| Full-Year Revenues | 2,389.8 | 100% | 8.8% | 3.0% |
Revenue by Audience in 2023
| 16% Doctors & Patients | 15% Citizens | 22% Clients & Employees | 47% Consumers |
| In million of euros | 2023 | Contribution | Organic Growth Q4 | Organic growth 2023 |
|---|---|---|---|---|
| Consumers1 | 1,126.8 | 47% | 12.8% | 7.1% |
| Clients and employees2 | 530.0 | 22% | 2.5% | 0.1% |
| Citizens3 | 351.2 | 15% | 2.3% | -5.0% |
| Doctors and patients4 | 381.8 | 16% | 12.4% | 3.6% |
| Full-Year Revenues | 2,389.8 | 100% | 8.8% | 3.0% |
Breakdown of each Service Line by segment: breakdown of revenue by audience segment is non-financial data, likely to change over time depending on changes to the organization of Ipsos teams.
1. Brand Health Tracking, Creative Excellence, Innovation, Ipsos UU, Ipsos MMA, Market Strategy & Understanding, Observer (excl. public sector), Ipsos Synthesio, Strategy3
2. Automotive & Mobility Development, Audience Measurement, Customer Experience, Channel Performance (including Mystery Shopping and Shopper), Media development, ERM, Capabilities
3. Public Affairs, Corporate Reputation
4. Pharma (quantitative and qualitative)
Summary consolidated financial statement
| In million of euros | 2023 | 2022 |
|---|---|---|
| Revenue | 2,389.8 | 2,405.3 |
| Gross profit | 1,612.8 | 1,594.1 |
| Operating margin | 312.4 | 314.7 |
| Adjusted net profit*, attributable to the Group | 228.6 | 232.4 |
| Workforce as of 31 December | 19,701 | 20,156 |
*Adjusted net profit is calculated before (i) non-cash items related to IFRS 2 (share-based compensation), (ii) amortisation of acquisition-related intangible assets (client relations), (iii) the impact net of tax of other noncurrent income, (iv) expense and the non-monetary impact of changes in puts in other financial income and expenses, (v) deferred tax liabilities related to goodwill for which amortisation is deductible in some countries.
Financial statement
| In million of euros | 2023 | 2022 |
|---|---|---|
| Total shareholders' equity | 1 433 | 1,500 |
| Financial debt | 120 | 69 |
| Free cash flow | 168,8 | 213.5 |
| Net debt / EBITDA | x 0,3 | x 0,2 |
Share capital and voting rights as at 31 December 2023
| Number of shares | % | Number of voting rights | % | |
|---|---|---|---|---|
| DT & Partners | 4,565,235 | 10.57 | 8,972,223 | 18.44 |
| Didier Truchot | 295,681 | 0.68 | 573,032 | 1.18 |
| Public | 37,080,225 | 85.83 | 37,185,344 | 76.4 |
| Employees | 1,245,327 | 2.88 | 1,938,455 | 3.98 |
| Including FCPE and Group savings plan | 14,764 | 0.03 | 28,797 | 0.06 |
| Treasury shares | 16,757 | 0.04 | 0 | 0.00% |
| Of which liquidity agreement | 7,052 | 0.02 | 0 | 0.00% |
| Total | 43,203,225 | 100 | 48,669,054 | 100 |